Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: eplerenone

Sortuj według:

Ogranicz wyniki do:

Nitric oxide as a modulator in platelet- and endothelium-dependent antithrombotic effect of eplerenone in diabetic rats

100%

Gromotowicz-Poplawska A., Kloza M., Aleksiejczuk M., Marcinczyk N., Szemraj J., Kozlowska H., Chabielska E.

Journal of Physiology and Pharmacology

2019

tom 70

nr 2

Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-gamma)

70%

Miana M., De Las Heras N., Rodriguez C., Sanz-Rosa D., Martin-Fernandez B., Mezzano S., Lahera V., Martinez-Gonzalez J., Cachofeiro V.

Journal of Physiology and Pharmacology

2011

tom 62

nr 1

Several factors, including mineralocorticoids, have been implicated in the renal damage associated with hypertension. Peroxisome proliferator activated receptor gamma (PPAR-) agonists improve renal damage associated with different pathologies. Therefore, our hypothesis was that mineralocorticoid receptor blockade ameliorates renal damage associated with hypertension and that this improvement may be mediated by PPAR-. Spontaneously hypertensive rats (SHR) were treated with either vehicle or eplerenone, a mineralocorticoid receptor antagonist, at two different doses: 30 and 100 mg/kg/day for 10 weeks. Age-matched Wistar Kyoto rats (WKY) were used as a normotensive reference group. SHR showed tubulointersticial fibrosis and mild tubular atrophy. These alterations were accompanied by increases in renal cortex gene expression of transforming growth factor beta (TGF-ß) connective tissue growth factor (CTGF) and phosphorylated Smad2 protein levels, factors involved in the fibrotic response. Interleukin 1-beta (IL-1ß) and tumor necrosis factor alpha (TNF-) gene expression were also increased. By contrast, lysyl oxidase (LOX) expression and PPAR- protein levels were decreased in SHR as compared with normotensive animals. Only the high dose of eplerenone was able to reduce blood pressure and partially prevent LOX down-regulation in SHR. Both eplerenone doses significantly ameliorated interstitial fibrosis and tubular atrophy, reduced TGF-ß, CTGF and cytokine gene expression, and decreased Smad2 activation, while normalizing PPAR- protein levels. Conclusions: Mineralocorticoid receptor activation participates in hypertension-associated renal damage. This effect seems to involve stimulation of both fibrotic and inflammatory processes mediated (at least in part) by a down-regulation of PPAR- that can favour an up-regulation of the TGF-ß/Smad signalling pathway.

Ograniczanie wyników

2 Journal of Physiology and Pharmacology

1 Aleksiejczuk M.

1 Cachofeiro V.

1 Chabielska E.

1 De Las Heras N.

1 Gromotowicz-Poplawska A.

1 Kloza M.

1 Kozlowska H.

1 Lahera V.

1 Marcinczyk N.

1 Martin-Fernandez B.

1 Martinez-Gonzalez J.

1 Mezzano S.

1 Miana M.

1 Rodriguez C.

1 Sanz-Rosa D.

1 Szemraj J.

1 2019

1 2011

Wyniki wyszukiwania

Nitric oxide as a modulator in platelet- and endothelium-dependent antithrombotic effect of eplerenone in diabetic rats

Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-gamma)